IONS

Ionis Pharmaceuticals (IONS)

Ionis Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IONS
DateTimeSourceHeadlineSymbolCompany
11/26/20214:06PMEdgar (US Regulatory)Current Report Filing (8-k) NASDAQ:IONSIonis Pharmaceuticals Inc
11/26/20218:16AMTipRanksIonis Reveals Results study of vupanorsen NASDAQ:IONSIonis Pharmaceuticals Inc
11/25/20214:10AMTipRanksIonis Pharmaceuticals (IONS) Gets a Hold Rating from Leerink Partners NASDAQ:IONSIonis Pharmaceuticals Inc
11/24/20219:30AMEdgar (US Regulatory)Current Report Filing (8-k) NASDAQ:IONSIonis Pharmaceuticals Inc
11/24/20217:29AMDow Jones NewsIonis Pharma: Clinical Study of Vupanorsen Meets Primary Endpoint NASDAQ:IONSIonis Pharmaceuticals Inc
11/24/20217:20AMSeeking AlphaIonis says that Pfizer reports topline results from Phase 2b vupanorsen study NASDAQ:IONSIonis Pharmaceuticals Inc
11/24/20216:30AMPR Newswire (US)Ionis announces that Pfizer reports topline results from Phase 2b clinical study of vupanorsen NASDAQ:IONSIonis Pharmaceuticals Inc
11/18/20211:30PMPR Newswire (US)Ionis initiates Phase 3 clinical program of donidalorsen in patients with hereditary angioedema NASDAQ:IONSIonis Pharmaceuticals Inc
11/12/20217:05AMPR Newswire (US)Ionis' antisense therapies to be featured at the American Heart Association (AHA) Scientific Sessions 2021 NASDAQ:IONSIonis Pharmaceuticals Inc
11/09/20217:05AMPR Newswire (US)Ionis to present at upcoming virtual investor conferences NASDAQ:IONSIonis Pharmaceuticals Inc
11/07/20217:05AMPR Newswire (US)Phase 2 study results of Ionis' novel antisense treatment for hereditary angioedema to be presented at ACAAI annual meeting NASDAQ:IONSIonis Pharmaceuticals Inc
11/03/20213:38PMEdgar (US Regulatory)Quarterly Report (10-q) NASDAQ:IONSIonis Pharmaceuticals Inc
11/03/20218:54AMSeeking AlphaIonis sees Q3 net loss more than double due to restructured operations, R&D costs NASDAQ:IONSIonis Pharmaceuticals Inc
11/03/20217:05AMSeeking AlphaIonis Pharmaceuticals EPS misses by $0.05, misses on revenue NASDAQ:IONSIonis Pharmaceuticals Inc
11/03/20217:00AMPR Newswire (US)Ionis reports third quarter 2021 financial results and recent business achievements NASDAQ:IONSIonis Pharmaceuticals Inc
11/02/202111:33AMSeeking AlphaIonis Pharmaceuticals Q3 2021 Earnings Preview NASDAQ:IONSIonis Pharmaceuticals Inc
11/02/20217:16AMSeeking AlphaIonis initiates late-stage olezarsen hypertriglyceridemia study NASDAQ:IONSIonis Pharmaceuticals Inc
11/02/20217:05AMPR Newswire (US)Ionis initiates pivotal Phase 3 clinical study of olezarsen in patients with severe hypertriglyceridemia NASDAQ:IONSIonis Pharmaceuticals Inc
10/20/20217:05AMPR Newswire (US)Ionis to hold third quarter 2021 financial results webcast NASDAQ:IONSIonis Pharmaceuticals Inc
10/19/20216:30PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4) NASDAQ:IONSIonis Pharmaceuticals Inc
10/19/20216:30PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4) NASDAQ:IONSIonis Pharmaceuticals Inc
10/19/20216:29PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4) NASDAQ:IONSIonis Pharmaceuticals Inc
10/18/20212:31PMEdgar (US Regulatory)Current Report Filing (8-k) NASDAQ:IONSIonis Pharmaceuticals Inc
10/18/202110:55AMDow Jones NewsIonis Pharma Shares Drop 12% After Tofersen Study Misses Primary Endpoint NASDAQ:IONSIonis Pharmaceuticals Inc
10/17/20214:20PMPR Newswire (US)Ionis' partner Biogen provides update on tofersen Phase 3 VALOR study in SOD1-ALS NASDAQ:IONSIonis Pharmaceuticals Inc
10/14/20214:06PMGlobeNewswire Inc.Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-ALS to be Presented at the American Neurological Association Annual Meeting NASDAQ:IONSIonis Pharmaceuticals Inc
09/30/202110:54AMDow Jones NewsVC Daily: Expansion Therapeutics Gets $80 Million for RNA-Targeted Drugs NASDAQ:IONSIonis Pharmaceuticals Inc
09/23/20213:34PMSeeking AlphaPTC Therapeutics slips after early stage results from Huntington's disease trial NASDAQ:IONSIonis Pharmaceuticals Inc
09/15/20217:30AMGlobeNewswire Inc.Biogen Plans to Initiate Phase 3b Study Evaluating Potential Benefit of a Higher Dose of Nusinersen in Patients Previously Treated with Evrysdi® (risdiplam) NASDAQ:IONSIonis Pharmaceuticals Inc
09/03/20217:05AMPR Newswire (US)Ionis to host ATTR symposium highlighting CARDIO-TTRansform Study at 3rd European ATTR Amyloidosis meeting NASDAQ:IONSIonis Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:IONS
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20211129 12:15:53